Business
Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSX...
About this update from Thiogenesis Therapeutics Corp
[{"type":"text","content":"Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria SymposiumSan Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (\"Thiogenesis\" or the \"Company\") a clinical-stage biotechnology company that is developing sulfur-containing compounds for unmet pediatric diseases, announced today that its CEO, Dr. Patrice Rioux, has been invited to lead a roundtable discussion on redox signaling at the 6th Annual Mitochondria Symposium at UCLA, in Los Angeles, California, on December 8, 2023.Reactive oxygen species (\"ROS\") have multiple biological functions. Importantly, they act as signaling molecules in the maintenance of fundamental physiological functions, a process termed \"redox biology\". For example, physical exercise generates ROS production, resulting in a number of beneficial pathways that are activated and that protect against cancer, diabetes, metabolic disease, and aging. Unfortunately, oxidative stress results when there is an imbalance from having too much ROS present and a deficiency of antioxidants necessary to detoxify them. Tissue damage occurs when there are elevated intracellular levels of ROS that can cause damage to lipids, proteins, and DNA. Oxidative stress from disease related mitochondrial dysfunction is at the core of many genetic and metabolic diseases. The generation of ROS is most prominent in the mitochondria - the powerhouse of cells. Thiogenesis' lead product, TTI-0102, is a precursor compound designed to meaningfully increase glutathione, a critically important intracellular antioxidant for controlling ROS and one that is uniquely active in the mitochondria.\"It is an honor to be invited to lead the roundtable at the UCLA Mitochondria Symposium on the important topic of redox signaling,\" said Dr. Rioux, Thiogenesis' CEO. \"The topic also has important implications for our lead compound, TTI-0102, which is a precursor to the antioxidant glutathione and has the potential to play a significant role in redox balance and in restoring a healthy, functioning mitochondria in a number of diseases.\" About The Mitochondria SymposiumThe Mitochondria Symposium at UCLA is a three-day conference starting on December 7, 2023 dedicated to exploring the world and science of the mitochondria - organelles that are the powerhouse of the cells...